What is the treatment for septic bursitis (infection of the bursae)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: April 21, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

Bursitis infection treatment should prioritize incision and drainage, as well as antibiotics effective against Gram-positive bacteria, including MRSA, to reduce morbidity and mortality. The management of bursitis infection is crucial to prevent complications and improve quality of life. According to the 2018 WSES/SIS-E consensus conference recommendations 1, empiric therapy for community-acquired MRSA (CA-MRSA) should be considered for patients at risk for CA-MRSA or who do not respond to first-line therapy.

Key considerations for bursitis infection treatment include:

  • Incision and drainage as the primary treatment for simple abscesses or boils, with antibiotics not needed for simple cases 1
  • Antibiotic therapy against Gram-positive bacteria, including streptococci and S. aureus, for superficial infections such as impetigo, erysipelas, and cellulitis 1
  • Empiric therapy for CA-MRSA for patients at risk or who do not respond to first-line therapy 1
  • Use of oral beta-lactams, macrolides, or lincosamides for mild cases, and parenteral route for more severe infections 1

In terms of specific antibiotic regimens, options may include cephalexin, dicloxacillin, or clindamycin for 7-10 days, with intravenous antibiotics reserved for severe cases. Supportive care, such as rest, ice, elevation, and over-the-counter pain relievers like ibuprofen or naproxen, can also help manage symptoms and improve quality of life. Prompt treatment is essential to prevent the infection from spreading and reducing the risk of complications.

From the Research

Bursitis Infection Treatment

  • Bursitis is typically caused by bacterial infections, with Staphylococcus aureus being a common culprit 2.
  • Treatment of bursitis infections often involves the use of antibiotics, with the choice of antibiotic depending on the severity of the infection and the susceptibility of the bacteria to different antibiotics.

Antibiotic Options

  • For methicillin-susceptible S. aureus (MSSA) infections, penicillinase-resistant penicillins (flucloxacillin, dicloxacillin) are the antibiotics of choice, while first generation cephalosporins (cefazolin, cephalothin and cephalexin), clindamycin, lincomycin and erythromycin may be used for less serious infections or in patients with penicillin hypersensitivity 2.
  • Cefazolin has been shown to be effective in treating S. aureus bacteraemia, with some studies suggesting it may be associated with lower mortality rates and less nephrotoxicity compared to anti-staphylococcal penicillins (ASPs) 3.
  • For patients with a beta-lactam allergy, cefazolin may still be a viable option for surgical site infection prevention after total joint arthroplasty, with one study finding it to be associated with decreased postoperative surgical site infections without an increase in interoperative hypersensitivity reactions 4.

Considerations

  • The choice of antibiotic should take into account the severity of the infection, the susceptibility of the bacteria, and the patient's medical history, including any allergies or hypersensitivities.
  • In cases where the bacteria are resistant to multiple antibiotics, combination therapy or the use of newer antibiotics such as linezolid or quinupristin/dalfopristin may be necessary 2.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Cefazolin versus anti-staphylococcal penicillins for the treatment of patients with Staphylococcus aureus bacteraemia.

Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases, 2019

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.